ÌÇÐÄÆƽâ°æ

In 2023, the total revenue of the Italian pharmaceutical group Recordati amounted to over two billion euros, most of which came from the production and marketing of specialty medicines.  Rare diseases drugs were the category generating the largest revenues, with over 714 million euros, followed by the branded drug Zanidip, which generated revenue for around 145 million euros. This statistic breaks down the revenue of Italian pharmaceutical company Recordati in 2023, by product (in 1,000 euros).